The Anti-Tumor Effect of Nab-Paclitaxel Proven by Patient-Derived Organoids.
anti-tumor
gastric cancer
nab-paclitaxel
organoid
Journal
OncoTargets and therapy
ISSN: 1178-6930
Titre abrégé: Onco Targets Ther
Pays: New Zealand
ID NLM: 101514322
Informations de publication
Date de publication:
2020
2020
Historique:
received:
05
11
2019
accepted:
27
05
2020
entrez:
3
7
2020
pubmed:
3
7
2020
medline:
3
7
2020
Statut:
epublish
Résumé
Nab-paclitaxel has been widely used in treating breast cancer and pancreatic patients for its low toxicity and high efficiency. However, its role in gastric cancer (GC) remains ambiguous. The aim of our study was to test the anti-tumor activity of nab-paclitaxel using GC patient-derived organoids. By using the organoid culture system, we describe the establishment of human gastric cancer organoid lines from surgical samples of three patients with gastric cancer. The consistency of these organoids with original cancer tissues was evaluated by histopathological examination. The characteristics of the cancer organoids were tested using immunofluorescence (IF) staining. Using organoids, the anti-tumor efficiencies of nab-paclitaxel, 5-Fu and epirubicin were compared by CCK8 assay and Annexin V-FITC/PI staining. Three organoids were successfully established and passaged. The morphology of the established GC organoids was consistent with original cancer tissues. The IC50 of nab-paclitaxel was 3.68 μmol/L in hGCO1, 2.41 μmol/L in hGCO2 and 2.91 μmol/L in hGCO3, which was significantly lower than those of 5-FU (72.99 μmol/L in hGCO1, 28.32 μmol/L in hGCO2 and 2.91 μmol/L in hGCO3) and epirubicin (25.85μmol/L in hGCO1, 15.15 μmol/L in hGCO2 and 7.60 μmol/L in hGCO3). When each organoid lines were treated with nab-paclitaxel for increasing period of time, the percentage of the apoptotic cells in each organoid increased accordingly. Nab-paclitaxel showed strong anti-tumor activity and had the potential to become front-line drug for treating GC patients. Gastric cancer organoid may be a good tool to predict in vivo response to drugs.
Sections du résumé
BACKGROUND
BACKGROUND
Nab-paclitaxel has been widely used in treating breast cancer and pancreatic patients for its low toxicity and high efficiency. However, its role in gastric cancer (GC) remains ambiguous. The aim of our study was to test the anti-tumor activity of nab-paclitaxel using GC patient-derived organoids.
METHODS
METHODS
By using the organoid culture system, we describe the establishment of human gastric cancer organoid lines from surgical samples of three patients with gastric cancer. The consistency of these organoids with original cancer tissues was evaluated by histopathological examination. The characteristics of the cancer organoids were tested using immunofluorescence (IF) staining. Using organoids, the anti-tumor efficiencies of nab-paclitaxel, 5-Fu and epirubicin were compared by CCK8 assay and Annexin V-FITC/PI staining.
RESULTS
RESULTS
Three organoids were successfully established and passaged. The morphology of the established GC organoids was consistent with original cancer tissues. The IC50 of nab-paclitaxel was 3.68 μmol/L in hGCO1, 2.41 μmol/L in hGCO2 and 2.91 μmol/L in hGCO3, which was significantly lower than those of 5-FU (72.99 μmol/L in hGCO1, 28.32 μmol/L in hGCO2 and 2.91 μmol/L in hGCO3) and epirubicin (25.85μmol/L in hGCO1, 15.15 μmol/L in hGCO2 and 7.60 μmol/L in hGCO3). When each organoid lines were treated with nab-paclitaxel for increasing period of time, the percentage of the apoptotic cells in each organoid increased accordingly.
CONCLUSION
CONCLUSIONS
Nab-paclitaxel showed strong anti-tumor activity and had the potential to become front-line drug for treating GC patients. Gastric cancer organoid may be a good tool to predict in vivo response to drugs.
Identifiants
pubmed: 32612367
doi: 10.2147/OTT.S237431
pii: 237431
pmc: PMC7322144
doi:
Types de publication
Journal Article
Langues
eng
Pagination
6017-6025Informations de copyright
© 2020 Xiao et al.
Déclaration de conflit d'intérêts
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
Lancet Oncol. 2018 May;19(5):629-638
pubmed: 29567071
ChemMedChem. 2012 Jun;7(6):952-72
pubmed: 22517723
J Pediatr Gastroenterol Nutr. 2019 Apr;68(4):509-516
pubmed: 30418409
Oncotarget. 2016 Jul 18;8(31):50557-50569
pubmed: 28881583
Cell. 2015 Jan 15;160(1-2):324-38
pubmed: 25557080
Biomaterials. 2017 Sep;140:162-169
pubmed: 28651144
Nat Rev Cancer. 2018 Jul;18(7):407-418
pubmed: 29692415
Eur J Cancer. 2019 Jan;107:46-52
pubmed: 30529902
J Gastric Cancer. 2012 Mar;12(1):3-6
pubmed: 22500257
JAMA Oncol. 2015 Jul;1(4):528-34; quiz 549
pubmed: 26181262
Gastric Cancer. 2019 Jan;22(1):155-163
pubmed: 29855738
Cell Mol Life Sci. 2018 Nov;75(22):4151-4162
pubmed: 30173350
Cancer Immunol Res. 2019 Dec;7(12):2065-2073
pubmed: 31615816
Nat Rev Cancer. 2019 Feb;19(2):65-81
pubmed: 30647431
J Clin Oncol. 2011 Dec 1;29(34):4548-54
pubmed: 21969517
Cell. 2018 Apr 5;173(2):515-528.e17
pubmed: 29625057
Expert Opin Pharmacother. 2006 Jun;7(8):1041-53
pubmed: 16722814
Ann Surg Oncol. 2002 May;9(4):394-400
pubmed: 11986192
Pediatr Nephrol. 2020 Feb;35(2):191-197
pubmed: 30607565
Cell. 2015 May 7;161(4):933-45
pubmed: 25957691
J Natl Cancer Inst. 1990 Aug 1;82(15):1247-59
pubmed: 1973737
Zhonghua Wei Chang Wai Ke Za Zhi. 2018 Feb 25;21(2):160-164
pubmed: 29492914
Eur J Cancer. 2018 Mar;91:86-91
pubmed: 29353164
Lancet Gastroenterol Hepatol. 2017 Apr;2(4):277-287
pubmed: 28404157
Cell Rep. 2018 Jul 31;24(5):1363-1376
pubmed: 30067989
J Control Release. 2013 Sep 28;170(3):365-72
pubmed: 23770008
PLoS One. 2013;8(2):e58037
pubmed: 23460921
Cancer Discov. 2018 Sep;8(9):1112-1129
pubmed: 29853643
Biomater Sci. 2019 Mar 26;7(4):1422-1436
pubmed: 30666997
Lab Chip. 2018 Mar 13;18(6):851-860
pubmed: 29437173
Mol Cancer Ther. 2016 Apr;15(4):680-8
pubmed: 26832793
BMC Cancer. 2019 Jan 8;19(1):28
pubmed: 30621630
Dev Biol. 2018 Jan 15;433(2):132-143
pubmed: 29291970
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
ANZ J Surg. 2019 Oct;89(10):1189-1190
pubmed: 31621167
Cell. 2018 Dec 13;175(7):1972-1988.e16
pubmed: 30550791
Ann Surg Oncol. 2007 Feb;14(2):317-28
pubmed: 17094022
Nat Med. 2017 Dec;23(12):1424-1435
pubmed: 29131160
Cell Stem Cell. 2018 Jun 01;22(6):929-940.e4
pubmed: 29779890
N Engl J Med. 2013 Oct 31;369(18):1691-703
pubmed: 24131140
Anticancer Res. 2018 Dec;38(12):6911-6917
pubmed: 30504409